Pentamethoxyamphetamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Pentamethoxyamphetamine (PeMA), also known as 2,3,4,5,6-pentamethoxyamphetamine (2,3,4,5,6-PeMA), 2,6-dimethoxy-TMA, or 3,6-dimethoxy-TMA-2, is a chemical compound of the phenethylamine and amphetamine families related to the psychedelic drug mescaline (3,4,5-trimethoxyphenethylamine).[1][2] It is the α-methyl or amphetamine derivative of pentamethoxyphenethylamine (PeMPEA).[1][2] The compound does not seem to have been tested in animals or humans.[1][2] However, the related drug PeMPEA is known to be behaviorally active in animal studies.[1][3] PeMA was first described in the scientific literature by Alexander Shulgin by 1969.[2] It is a controlled substance in Canada under phenethylamine blanket-ban language.[4]
- None
 | |
| Clinical data | |
|---|---|
| Other names | PeMA; 2,3,4,5,6-Pentamethoxyamphetamine; 2,3,4,5,6-PeMA; 2,6-Dimethoxy-TMA; 3,6-Dimethoxy-TMA-2 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C14H23NO5 |
| Molar mass | 285.340 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
